, and was until late 2010 director of the Steno Diabetes Centre, which is owned by Novo Nordisk and holds shares in Novo Nordisk. T. Lauritzen has been lecturing for Novo Nordisk, holds shares in Novo
sanofi-aventis, the American Diabetes Association and academic societies. T. Lauritzen has received honoraria for invited lectures from industry, approximately 5,000, during the past year; he also holds
Aims/hypothesisRecent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to several chronic diseases, including type 2 diabetes. suPAR is also associated with adiposity and smoking. We hypothesised that this biomarker would be linked to incident type 2 diabetes in individuals with impaired glucose...
holds shares in Novo Nordisk A/S. He has received lecture fees from Novo Nordisk, Bristol-Myers Squibb, Novartis, Pfizer, Hermedico and AstraZeneca. T. Lauritzen has received lecture fees of approximately
S. S. Rasmussen C. Glmer A. Sandbaek T. Lauritzen K. Borch-Johnsen Aims/hypothesis To estimate the 1-year progression rates from both IFG and IGT to diabetes in individuals identified in a pragmatic
Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance. An important and consistent pathophysiological finding is the failure to produce adequate increments in insulin secretion in response to carbohydrate intake. Therefore, insulin secretagogue therapy, particularly when focused...
Aims/hypothesisThe yield of screening programmes for Type 2 diabetes in the existing healthcare setting might be lower than anticipated from tests of screening algorithms in data from epidemiological surveys. Our aims were to evaluate the reliability of the algorithms and the effectiveness of a proposed stepwise screening programme for Type 2 diabetes in general practice...
Aims/hypothesis The list of validated type 2 diabetes susceptibility variants has recently been expanded from three to 19. The variants identified are common and have low penetrance in the general population. The aim of the study is to investigate the combined effect of the 19 variants by applying receiver operating characteristics (ROC) to demonstrate the discriminatory value...
Aim/hypothesisRecently, variants in WFS1 have been shown to be associated with type 2 diabetes. We aimed to examine metabolic risk phenotypes of WFS1 variants in glucose-tolerant people and in individuals with abnormal glucose regulation.MethodsThe type 2 diabetes-associated WFS1 variant rs734312 (His611Arg) was studied in the population-based Inter99 cohort involving 4,568...
Obesity was sponsored by Novo Nordisk A=S 6 ADDITION: Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care. Principal investigators: T Lauritzen and K
-of-care improvement activities (see http://www.dawnstudy. com). M. Peyrot performed the statistical analysis. M. Peyrot and R. R. Rubin drafted the paper. T. Lauritzen, S. E. Skovlund, F. J. Snoek, D ... M. Peyrot are on the International DAWN Advisory Panel. M. Peyrot, R. R. Rubin, T. Lauritzen and R. Landgraf have received grants, and fees for consulting and lecturing from Novo Nordisk, the sponsor
Aims/hypothesisRecent genome-wide association studies have suggested that a polymorphism in GCKR, the gene encoding the glucokinase regulatory protein, is involved in triacylglycerol regulation. Our aim was to examine in large-scale studies the common GCKR rs780094 polymorphism in relation to metabolic traits (mainly fasting hypertriacylglycerolaemia) and traits related to...
for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital , Old Road, Headington, Oxford OX3 7LJ, UK 1 T. Lauritzen Department of General Practice, University of ... , Gentofte, Denmark (principal investigator), T. Lauritzen, University of Aarhus, Denmark (principal investigator) and A. Sandbk, University of Aarhus, Aarhus, Denmark. The study was supported by the National
. Mathiesen T. Jensen T. Lauritzen T. Deckert Steno Memorial Hospital Gentofte Denmark Summary. We re-examined 69 of the 70 patients entering the two independent Steno Studies of effects of improved metabolic ... , Oxenbr R , Johansen K , Svendsen PA , Deckert T ( 1984 ) Incipient nephropathy in Type 1 (insulin-dependent) diabetes . Diabetologia 26 : 406 - 410 18. Deckert T , Lauritzen T , Parving H-H , Christiansen
Diabetologia Pharmacokinetics of Continuous Subcutaneous Insulin Infusion 0 Steno Memorial Hospital and Hagedorn Research Laboratory , Gentofte , Denmark 1 T. Lauritzen, S. P r a m m i n g , T. D e
. University Hospltal Leiden , The, Netherlands., TREATMENT WITH hGH IIAS NO EFFECT ON ADULT HEIGHT IN, IIYPOPITUITARY CIIILDREN 3 T. Lauritzen*, H. Orskov* (Introd. by N. Skakkebzk)., Second University Clinic
T. Lauritzen*, JOL. Jsrgensen*, A. Flyvbjerg*, JS. 0 J.J. VAN DER WERFF TEN BOSCH and A. DOT 1 JOL. Jorgensen*, JS. Christiansen*, A. Flyvbjerg*, 2 0 Christiansen*. H. Orskov* ( I n t r o d . by N ... Department of, Endocrinology. University Hospltal Leiden , The , Netherlands. , TREATMENT WITH hGH IIAS NO EFFECT ON ADULT HEIGHT I N, IIYPOPITUITARY CIIILDREN 2 T. Lauritzen*, H. Orskov* ( I n t r o d . by N
d insulin a b s o r b e d in t h e p r e c e d i n g 3 to 6 h o u r s was f o u n d in all p a t i e n t s ( T a b l e 3), b e i n g 0.73 for t h e p a t i e n t in T. Lauritzen et 'al.: t25I-Insulin ... statistically T. Lauritzen et al.: ~25I-Insulin Absorption and Blood Glucose Concentration significant at the 5% level in all but one patient. The latter patient [ 1 ] had only been treated with insulin for 2
Diabetologia Glycosylated Haemoglobin a n d Steady-State Mean Blood Glucose Concentration in Type 1 (Insulin-Dependent) Diabetes P. A a b y Svendsen T. Lauritzen U. S o e g a a r d a n d J. N e r u
J.O.L. Jergensen*. J. Meller*. T. Lauritzen*. &J 0 A. Massarano*, R. Stanhope, P.J. Pringle*, 1 0 Christiansen* (Introd. by N.E. Skakkebek)., Second University Clinic of Internal Medicine.Aarhus